Literature DB >> 29781505

Cerebral vasculopathy in childhood neurofibromatosis type 2: cause for concern?

Karine Lascelles1,2, Shazia Afridi2, Ata Siddiqui1, Cheryl Hemingway3, Rosalie Ferner2, Vijeya Ganesan3,4.   

Abstract

Unlike adult neurofibromatosis type 2 (NF2), which presents with symptoms related to bilateral vestibular schwannomas, children with NF2 most frequently present with ocular, dermatological, and neurological symptoms. Arteriopathy, a well-established feature in neurofibromatosis type 1, is not a widely recognized feature of NF2. Here we report three children with NF2 with cerebral arteriopathy and/or arterial ischaemic stroke. Bevacizumab, a vascular endothethial growth factor inhibitor, is an established treatment for rapidly growing vestibular schwannomas; however, it carries a risk of both ischaemic and haemorrhagic stroke. Thus, the role of screening and risk to benefit ratio of bevacizumab in NF2 merit further consideration. WHAT THIS PAPER ADDS: Children with neurofibromatosis type 2 (NF2) may be at increased risk of cerebral vasculopathy and arterial ischaemic stroke. Targeted magnetic resonance angiography should be performed in children with NF2 who are being considered for bevacizumab therapy.
© 2018 Mac Keith Press.

Entities:  

Mesh:

Year:  2018        PMID: 29781505     DOI: 10.1111/dmcn.13920

Source DB:  PubMed          Journal:  Dev Med Child Neurol        ISSN: 0012-1622            Impact factor:   5.449


  2 in total

1.  Report on a child with neurofibromatosis type 2 and unilateral moyamoya: further evidence of cerebral vasculopathy in NF2.

Authors:  Claudia Santoro; Federica Palladino; Pia Bernardo; Giuseppe Cinalli; Giuseppe Mirone; Teresa Giugliano; Giulio Piluso; Silverio Perrotta
Journal:  Neurol Sci       Date:  2019-01-21       Impact factor: 3.307

2.  Brainstem ischemic syndrome in juvenile NF2.

Authors:  John W Henson; Tara Benkers; Connor McCormick
Journal:  Neurol Genet       Date:  2020-06-16
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.